Create a narrative

Lexicon Pharmaceuticals Community

NasdaqCM:LXRX Community

1 Narratives written by author
2 Comments on narratives written by author
23 Fair Values set on narratives written by author

Create a narrative

Lexicon Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 5 Analysts

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options

Key Takeaways Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets. Strategic licensing and cost reduction initiatives aim to boost revenue streams while improving net margins and profitability.

US$3.05

FV

64.6% undervalued

-2.93%

Revenue growth p.a.

0

2

20

Updated